Evidence of the neuron-restrictive silencer factor (NRSF) interaction with Sp3 and its synergic repression to the mu opioid receptor (MOR) gene by Kim, Chun Sung et al.
Evidence of the neuron-restrictive silencer factor
(NRSF) interaction with Sp3 and its synergic
repression to the mu opioid receptor (MOR) gene
Chun Sung Kim*, Hack Sun Choi, Cheol Kyu Hwang, Kyu Young Song,
Byung-Kwon Lee
1, Ping-Yee Law, Li-Na Wei and Horace H. Loh
Department of Pharmacology, University of Minnesota Medical School, 6-120 Jackson Hall, 321
Church Street SE, Minneapolis, MN 55455, USA and
1Department of Microbiology, University of Tennessee,
Knoxville, TN 37996, USA
Received May 18, 2006; Revised and Accepted September 19, 2006
ABSTRACT
Previously, we reported that the neuron-restrictive
silencer element (NRSE) of mu opioid receptor
(MOR) functions as a critical regulator to repress
the MOR transcription in specific neuronal cells,
depending on neuron-restriction silence factor
(NRSF) expression levels [C.S.Kim, C.K.Hwang,
H.S.Choi, K.Y.Song, P.Y.Law, L.N.Wei and H.H.Loh
(2004) J. Biol. Chem., 279, 46464–46473]. Herein, we
identify a conserved GC sequence next to NRSE
region in the mouse MOR gene. The inhibition of Sp
family factors binding to this GC box by mithramy-
cin A led to a significant increase in the endogenous
MOR transcription. In the co-immunoprecipitation
experiment, NRSF interacted with the full-length Sp3
factor, but not with Sp1 or two short Sp3 isoforms.
The sequence specific and functional binding by
Sp3 at this GC box was confirmed by in vitro gel-
shift assays using either in vitro translated proteins
or nuclear extract, and by in vivo chromatin immuno-
precipitation assays. Transient transfection assays
showed that Sp3-binding site of the MOR gene is a
functionally synergic repressor element with NRSE
in NS20Y cells, but not in the NRSF negative PC12
cells. The results suggest that the synergic interac-
tion between NRSF and Sp3 is required to negatively
regulate MOR gene transcription and that transcrip-
tion of MOR gene would be governed by the context
of available transcription factors rather than by a
master regulator.
INTRODUCTION
The mu opioid receptor (MOR) plays an important role in
mediating the actions of morphine and morphine-like drugs.
Based largely on pharmacological and clinical observations,
MOR has traditionally been considered the main site of
interaction of the major clinically used analgesics, particu-
larly morphine (1). Three major types of opioid receptors,
m, d and k, have been cloned and shown to belong to the
G-protein-coupled receptor superfamily (2). Regulation of
the opioid receptor gene expression may be in response to
ﬂuctuating levels of various agents in certain brain regions.
Thus, study of the mechanism underlying the transcriptional
regulation of opioid receptor genes may facilitate elucidation
of the spatial and temporal expressions and the modulation of
expression in different physiological states.
The expression of mouse MOR gene is known to be
regulated by various cis-acting elements and trans-acting fac-
tors, which are important for promoter activity (3–9). It has
been reported that a major species of mRNA and polyadeny-
lation signal of MOR has promoter-dependent functional
activity (10). We have also reported that MOR transcription
is suppressed by the neuron-restrictive silencer element
(NRSE) in the mouse MOR promoter through binding of
neuron-restriction silence factor (NRSF) (11).
In both non-neuronal and neuronal cells, NRSF silences the
expression of its target genes by its two independently acting
repressor domains (12,13). The N-terminal repressor domain
of NRSF has been shown to recruit co-repressors, such as
mSIN3 and histone deacetylases (HDACs), into the vicinity
of the promoter. Histone deacetylation leads to a more
compact chromatin that prevents accessibility of transcription
factors. The C-terminal repressor domain (CTRD) of NRSF
has been shown to interact with at least one factor, the tran-
scriptional co-repressor 2 (CoREST) that may serve as a
platform protein for the recruitment of molecular machinery
that imposes silencing across a chromosomal interval (14,15).
CoREST is able to interact with HDAC1/2, indicating that the
CTRD also contributes to deacetylation of histones (16).
Some studies have revealed the existence of additional
repression mechanisms mediated by NRSF. This has been
postulated because HDAC inhibitors fail to derepress the
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receptor and SCG10 (17,18). In addition, overexpression of
the dominant-negative NRSF and knock-out of NRSF failed
to release the repression of its target gene completely, even
though NRSF was originally deﬁned as a repressor for
neuronal-speciﬁc gene in non-neuronal cells. Therefore,
from recent studies, it has become clear that genetic context
is extremely important in determining the function of NRSE/
NRSF repression mechanisms.
In this study, we have identiﬁed a conserved GC box (Sp
family binding site) sequence downstream of NRSE region
in the mouse MOR gene. Our results have showed that Sp3
speciﬁcally binds to this mouse GC box and interacts with
NRSF to synergistically repress the MOR expression.
MATERIALS AND METHODS
Cell culture and reporter gene constructs
NS20Y and HeLa cells were routinely grown in DMEM
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) at 37 C in a humidiﬁed atmosphere of 5% CO2.
PC12 cells were cultured in 10% CO2 in DMEM with 10%
donor horse serum and 5% FBS (7).
The pGL4.7 ( 4744 to +1, the translation start site was
designated as +1) was generated by ligation of the PCR
product ( 249 to +1) with the BamHI and NcoI digested
pL4.7K ( 4744 to  249) (19). PCR was performed using
genomic DNA from mouse NS20Y cells as a template and
an upstream sense oligonucleotide (50-GCCTCTGGATCCCT
CACAGCCCAT-30), containing a BamHI site, and a down-
stream antisense oligonucleotide (50-GGCGCTGCTGTCCAT
GGTTCTGAA-30) containing a NcoI site. The pGL4.7NRSP,
pGL4.7preNRmSP, pGL4.7NRSPm and pGL4.7preNRmSPm
constructs were generated by ligation of the pGL4.7 DNA
digested with NcoI and the double-strand oligomers
(pGL4.7NRSP; wild type of NRSE and Sp-binding sequence,
pGL4.7NRmSP; mutated NRSE and wild type of Sp-binding
sequence, pGL4.7NRSPm; wild type of NRSE and mutated
Sp-binding sequence, pGL4.7NRmSPm; mutated NRSE
and mutated Sp-binding sequence) containing NcoI site
at both 50 and 30 ends (for pGL4.7NRSP: 50-TTCAGA
ACCATGGACAGCAGCGCGCCGGCCCATGGATTCTTC
-30; for pGL4.7preNRmSP: 50-TTCAGA ACCATGGA ATA
GTTGCGCGCCGGCCCATGGATTCTTC-30; for pGL4.7
NRSPm: 50-TTCAGAACCATGGACAGCAGCGCATATGC
CCATGGATTCTTC -30; for pGL4.7preNRmSPm: 50-TTCA
GAACCATGGAATAGTTGCGCATATGCCCATGGATTC
TTC-30) (The underlines indicate mutated nucleotides for
NRSE and Sp3 core binding sites).
The pGL4.7NRmSP and pGL4.7NRmSPm constructs were
ﬁnally generated by PCR site-directed mutagenesis using
high-ﬁdelity Pfu DNA polymerase according to the manufac-
turer’s protocol (Quikchange TM; Stratagene). In vitro muta-
genesis was carried out on MOR promoter linked to
luciferase gene reporter (pGL4.7preNRmSP and pGL4.7pre
NRmSPm) using primers as follows: for pGL4.7NRmSP:
50-TTCAGAACCATAAAATAGTTGCGCGCCGGCCCAT
GGATTCTTC-30;5 0-GAAGAATCCATGGGCCGGCGCGC
AACTATTTTATGGTTCTGAA-30; for pGL4.7NRmSPm:
50-TTCAGAACCATAAAATAGTTGCGCATATGCCCAT
GGATTCTTC-30;5 0-GAAGAATCCATGGGCATATGCGC
AACTATTTTATGGTTCTGAA-30).Themutatednucleotides
are underlined.
Total RNA preparation and RT–PCR analysis
Total RNA was isolated according to the supplier’s protocol
(TRI Reagent; Molecular Research Center, Inc.). For
RT–PCR, 2 mg of total RNA was reverse transcribed and
PCRs were carried out with MOR-speciﬁc primers at the
same tube using one-step RT–PCR reagent (Qiagen) in a
GeneAmp 9600 PCR machine (Perkin-Elmer). The PCR
cycle conditions for MOR consisted of 95 C for 45 s, 60 C
for 45 s and 72 C for 45 s, followed by a 10 min extension
at 72 C (37 cycles for NS20Y, 33 cycles for PC12 cell).
PCR products were separated in a 2.0% agarose gel with
TBE buffer. The mouse MOR transcript was ampliﬁed with
primer set P2Ss (50-CTCCGTGTACTTCTAAGGTGGGAG-
30) and TM2as (50-GGCTAAGGCATCTGCCAGAGCAAG-
30). Similar reactions were carried out using primers for
b-actin as an internal control. Quantitative analyses were
carried out using ImageQuant 5.2 (Amersham) software.
Transient transfection and reporter gene assay
For luciferase assays, 1 · 10
6 cells/well were cultured
overnight before transfection. Various reporter constructs
at equimolar concentrations were transfected using Effectene
transfection reagent (Qiagen, Valencia, CA) as described
previously (11). After 48 h of transfection, cells were washed
twice with phosphate-buffered saline (PBS) and lysed
with lysis buffer (Promega). For all the assays, pCH110
(b-galactosidase; Amersham Bioscience Inc.) was also co-
transfected and measured to normalize transfection efﬁci-
ency. The luciferase and b-galactosidase activities were
determined according to the manufacturer’s instructions
(Promega and Tropics, Madison, WI).
Real-time PCR
Total RNA was extracted using the TRIzol reagent (Molecu-
lar Research Center, Inc.) from NS20Y cells. DNase I-treated
RNA (2 mg) was subjected to RT (Roche) using oligo(dT)
primer. One-fortieth of this reaction was used for real-time
PCR analysis using SYBR Green I dye chemistry. PCR prod-
uct accumulation was monitored using a iCycler iQ Real-
Time detection system (Bio-Rad). The mean cycle threshold
value (Ct) from triplicate samples was used to calculate gene
expression level. PCR products were normalized to levels of
b-actin. Relative gene expression levels were determined as
described in User’s resource guide from Bio-Rad.
Co-immunoprecipitation and western blots
Cells were lysed in a buffer containing 1% Triton X-100,
10 mM Tris, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, sup-
plemented with 1 mg/ml antipain, 1 mg/ml leupeptin, 100 nM
PMSF and 100 nM sodium orthovanadate. Approximately
1 mg of the clariﬁed cell lysate was incubated overnight at
4 C with an anti-Sp1, anti-Sp3 or anti-NRSF monoclonal
antibody. Immunoprecipitates were recovered on protein
G–Sepharose beads, washed extensively and separated on
SDS–PAGE. Proteins were transferred on to PVDF mem-
brane (Amersham Biosciences). Membranes were incubated
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(sc-59; Santa Cruz Biotechnology) and anti-NRSF antibody
(12C11; kindly provided by Dr David Anderson) and signals
were detected using a Storm 840 PhosphorImager system
(Amersham Biosciences).
Electrophoretic mobility shift assay
In vitro translation of NRSF and Sp3 was performed using the
TNT SP6 and T7 Quick Coupled Transcription/Translation
System as per the manufacturer’s protocol (Promega) and
nuclear extracts from NS20Y cells were prepared as
described previously (11). Double-stranded oligonucleotides
containing a copy of the MOR NRSE/GC box (50-CAGCAA
GCATTCAGAACCATGGACAGCAGCGCCGGCCCAGG-
GA-30) were synthesized and end-labeled using the Klenow
fragment of DNA polymerase I in the presence of [g-
32-
P]dATP. Free nucleotides were separated by centrifugation
through a G-25 column (Roche). The end-labeled DNA
probes were incubated with in vitro translated NRSF or Sp3
or both and with nuclear extract from NS20Y cells. For com-
petition analysis, a 100-fold molar excess of cold competitor
oligonucleotide was added to the mixture before adding the
probe. For supershift assay, antibodies or pre-immune
serum were pre-incubated for 30 min on ice before adding
the labeled probe. Radiolabeled probe was then added and
the mixture was incubated for further 20 min on ice. Samples
were subjected to electrophoresis on a native 4% polyacry-
lamide gel run in 0.5· TBE buffer for 2 h at 180 V. Mono-
clonal antibody against NRSF was obtained from Dr D. J.
Anderson. Anti-IRF4 antibody was purchased from Santa
Cruz Biotechnology.
Chromatin immunoprecipitation (ChIP) and re-
precipitation (re-ChIP)
ChIP assay was performed as described by Kim et al. (11).
Brieﬂy, cells were incubated for 15 min in a medium contain-
ing 1% formaldehyde at room temperature and cross-linking
was quenched by adding glycine to 125 mM. Cells were
washed three times with ice-cold Tris-buffered saline (150
mM NaCl and 20 mM Tris–HCl, pH 7.6), resuspended in
lysis buffer and disrupted on ice with a sonicator followed
by centrifugation at 15 000 g for 10 min to remove cell deb-
ris. Gel electrophoresis indicated that a substantial fraction of
DNA fragments at this stage are from 0.3 to 3.0 kb in length.
ChIP was performed by incubating the cell lysate overnight at
4 C with 4 mg of anti-Sp1, anti-Sp3, anti-HDAC1, anti-
HDAC2 or anti-IRF4 (as a non-speciﬁc antibody) followed
by incubation with protein G Plus–agarose (Santa Cruz
Biotechnology) for 2 h. The beads were rinsed four times
sequentially with lysis buffer 500 (0.1% deoxycholic acid,
1 mM EDTA, 50 mM HEPES, pH 7.5, 500 mM NaCl and
1% Triton X-100), LiCl/detergent solution (0.5% deoxycholic
acid, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40 and 10 mM
Tris–HCl, pH 8.0) and TE buffer (10 mM Tris–HCl, pH 8.0
and 1 mM EDTA, pH 8.0). The beads were then incubated for
10 min at 65 C with elution buffer (10 mM EDTA, 1% SDS
and 50 mM Tris–HCl, pH 8.0).
For re-ChIP, re-ChIP elution buffer (10 mM EDTA, 50
mM Tris–HCl, pH 8.0 and 0.7 M NaCl) was used. To reverse
the cross-linking and purify the DNA, the precipitates were
incubated at 65 C overnight and then treated with proteinase
K solution for 2 h at 37 C. DNA samples were recovered and
resuspended in TE buffer. PCRs were performed using 4 mlo f
immunoprecipitated chromatin sample with the primers span-
ning mouse MOR promoter region in 50 ml of total volume.
Primers used were NSCF forward, 50-CTGTGAGAGGAAG
AGGCTG-30 and NSCR reverse, 50-AAGTTGAGCCAGGA
GCCAGGT-30, which produces 188 bp PCR products.
RESULTS
Mithramycin A up-regulates the endogenous MOR
transcription
Previously, we reported that the MOR transcription is
suppressed by NRSE in the mouse MOR promoter through
binding of NRSF (11). In the current study, we have studied
the role of G/C box sequences (GGGGGCGGGGC), identi-
ﬁed in mouse, rat and human in adjacent to NRSE, which
is a consensus nucleotide-binding sites for the Sp transcrip-
tion factors (Figure 1A). To assess the functionality of the
putative Sp factor binding site on the expression of the
MOR genes, NS20Y cells were treated with mithramycin A,
a DNA-binding blocking drug that inhibits the binding of
transcription factor to G/C-speciﬁc regions of DNA. Mithra-
mycin A is a cell-permeable agent that binds GC-rich DNA
sequences and is frequently used to explore the sequence
dependency of DNA-binding factors (20). As shown in
Figure 1B and D, RT–PCR and real-time RT–PCR revealed
that the mRNA levels of the MOR were increased by mithra-
mycin A treatment in a dose-dependent manner in the NRSF
positive NS20Y cells. However, in the NRSF negative PC12
cells, MOR transcript level was not affected by mithramycin
A treatment (Figure 1C). In accordance with other studies,
mithramycin A did not change mRNA levels of b-actin
(21). These results indicated that the putative Sp-binding
site may mainly act as a negative element for the expression
of MOR gene in NS20Y cells.
The Sp-binding site and NRSE synergistically repress
the expression of MOR gene
Independent studies have shown that Sp1 has functional
implication in expression of some of NRSF target genes
including N-methyl-D-aspartate receptors, dynamin I, synap-
tophysin and glutamate receptor ionotropic kainate-5 genes
(22–24). For MOR gene regulation, Sp1 factor acts as a
major positive regulator by binding two cis-elements (distal
and proximal promoters) located at  340 through  300 resi-
dues from the translation start site while Sp3 has a minor
effect by binding to one of these elements (25). As mentioned
above, a computer search identiﬁed a G/C box sequence at
the downstream of NRSE region. To verify the functionality
of this motif in MOR transcription, we generated various
MOR/luciferase reporter constructs containing pGL4.7NRSP
(wild type), pGL4.7NRmSP (mutated NRSE and wild-type
Sp-binding site), pGL4.7NRSPm (wild-type NRSE and
mutated Sp-binding site), pGL4.7NRmSPm (mutated both
in NRSE and Sp-binding site) (Figure 2A). All the constructs
had been generated in more than 4.7 kb MOR promoter
region containing distal and proximal elements and possibly
other unidentiﬁed elements that might have roles in the
6394 Nucleic Acids Research, 2006, Vol. 34, No. 22promoter activity. Thus, the promoter assay in the current
study may accurately reveal the role of newly identiﬁed GC
box in the MOR gene regulation.
The constructs were transiently transfected in NS20Y and
PC12 cells separately and the promoter activity was exam-
ined by measuring the signal of the reporter gene. As
expected, the mutation in either NRSE or GC box sequence
increased the expression of reporter gene in NS20Y cells
(Figure 2B). Interestingly, when both elements were mutated
at the same time, the promoter activity (14-fold in NS20Y
cell) was repeatedly greater than the sum of activities from
the constructs where each element was mutated singly
(4-fold in Sp site mutation and 6-fold in NRSE mutation).
Therefore, these data indicate that NRSE and Sp-binding
Figure 1. Mithramycin A activates expression of the endogenous MOR gene. (A) The putative Sp family binding site and NRSE sequence among three species,
mouse, human and rat is located from  9t o+20 in the MOR gene and have highly homologous (*) sequence to the consensus Sp family binding site and NRSE
DNA element. (B) NS20Y cells (NRSF positive cells) were pre-incubated with mithramycin A (5, 10, 20, 50 and 100 nM) for 24 h. Total RNAs were prepared
and analyzed by RT–PCR for the MOR gene expression using specific primer pairs as described in Materials and Methods. Expression of the b-actin gene that is
insensitive to mithramycin A was used as a negative control. (C) PC12 cell (NRSF negative cells) was pre-incubated with mithramycin A (10, 50, 100 nM) for 24
h. (D) Quantification of transcripts was performed with real-time quantitative PCR (RT-qPCR). NS20Y cells were treated either DMSO or 50 nM of mithramycin
A for 24 h. Total RNA was prepared and treated with DNase I, and primer pairs specific for the coding sequence of each gene were used for RT-qPCR with the
dye SYBR Green. The mRNA levels from DMSO or mithramycin A treated cells were normalized to b-actin levels. Error bars indicate the range of SE and
threshold cycle (Ct) values were obtained from triplicate data points and changes in transcript levels for mithramycin A treated samples were compared with
DMSO-treated samples, which were assigned a value of 1.
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Meanwhile, the activities of the same reporter constructs in
the NRSF negative PC12 cells (judged from the western
blot in Figure 2C) had little effect (Figure 2B) on the pro-
moter activity. These data suggest that a putative Sp-binding
site acts as a synergic repressor with NRSE in NS20Y
cells and NRSF and NRSE plays an important role to decide
the function of the newly identiﬁed Sp-binding site as a
repressive cis-element.
In addition, we also investigated whether the transcrip-
tional repression activity of the putative Sp-binding site in
the MOR promoter can be relieved in the NS20Y cells after
mithramycin A treatment. NS20Y cells were transiently
transfected either with pGL4.7NRSP or pNRSPm constructs
(Figure 3A). Twenty-four hours after transfection, the cells
were treated with either 100 or 400 nM mithramycin A.
When the wild-type promoter sequence (pGL4.7NRSP)
was transfected, a dose-dependent increase in the promoter
activity was observed (Figure 3B). In contrast, when the
putative Sp-binding site was mutated (pGL4.7NRSPm), the
high promoter activity was detected even without treatment
of mithramycin A strongly supporting the notion that this
putative Sp-binding site downregulates expression of the
MOR gene. Interestingly, at the highest concentration, mithra-
mycin A started to decrease the promoter activity. At this
condition, mithramycin A could interfere the binding of
positive transcriptional regulators such as Sp1 within the
promoter region.
Figure 2. The NRSE- and Sp-binding site additively repress the MOR promoter activity in NS20Y but not in PC12 cells. (A) Schematic diagram representing the
constructs of the mouse MOR promoter/luciferase from nucleotide  4.7 kb to +20 bp, containing the translation start site (ATG), which is designated +1 and
showing NRSE and putative Sp-binding sequences. (B) NS20Y and PC12 cells individually were transfected with the pGL4.7NRmSPm (mutated the both of
NRSE and Sp-binding sites), pGL4.7NRSP (wild-type promoter), pGL4.7NRmSP (mutated the NRSE site) and pGL4.7NRSPm (mutated the Sp-binding site)
reporter constructs. The promoter activity of each construct was expressed as relative luciferase activity, and transfection efficiencies were normalized to
b-galactosidase activity by co-transfection of the internal control plasmid pCH110. Error bars indicate the range of SE, and the activities of the luciferase reporter
were expressed as n-fold relative to the activity of each corresponding luciferase reporter with vector-alone transfection, which was assigned an activity value of
1.0. (C) Analysis of NRSF expression in NS20Y and PC12 cells by western blotting.
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NRSE to repress transcription of MOR gene
Co-immunoprecipitation was performed to identify a subclass
of Sp factors responsible for the observed repressor activity in
the transcription of MOR gene. The lysates from HeLa cells
were immunoprecipitated with Sp1, Sp3, NRSF antibody and
pre-immune serum (PI) (as a negative control) and subjected
to SDS–PAGE followed by western blot analysis with NRSF
and Sp3 antibody. The endogenous Sp3 factor and NRSF
were co-immunoprecipitated with NRSF and Sp3 antibody,
respectively. In contrast, Sp1 did not co-precipitate with
NRSF antibody (Figure 4A). The same result was obtained
using c-Myc-tagged NRSF expressed in NS20Y cells
implying that Sp3 binds the GC box and a direct interaction
between Sp3 and NRSF is required for a synergistic
repression of MOR gene expression (Figure 4B). In addition,
immunoprecipitation experiment revealed that only the
full-length Sp3 factor, other than two short Sp3 isoforms
(M1 and M2), interact with NRSF (Figure 4C).
To conﬁrm the binding of Sp3 to the putative GC box, we
performed a supershift assay with in vitro translated proteins
(myc-NRSF, Sp3) and nuclear extract from NS20Y and PC12
cells. In the electrophoretic mobility shift assay (EMSA) with
in vitro translated proteins, both NRSF (Figure 5A) and Sp3
(Figure 5B) formed a binary complex with the labeled probe
(from  18 to +24 of MOR). In both cases, cold competitor
completely eliminated the binary complex indicating the
sequence-speciﬁc binding of NRSF and Sp3 to NRSE/GC
box. Moreover, the super shift of the binary complex were
observed when incubated with anti-c-myc or anti-Sp3 anti-
body demonstrating the speciﬁc binding of two transcription
factors to the probed DNA sequences. The incubation with PI
or IRF-4 (non-speciﬁc antibody as a negative control) had no
effect in either NRSF or Sp3 bound complex.
Since the binding site in DNA for both NRSF and Sp3 are
slightly overlapped and co-immunoprecipitation experiment
suggests that NRSF and Sp3 interact with each other, we
tested whether both NRSF and Sp3 can bind the labeled
probe at the same time without any interference. As shown
in Figure 5C, incubation of increased amount of Sp3 to the
ﬁxed amount of NRSF generated a new ternary complex
indicating that NRSF and Sp3 bind this short MOR promoter
sequence. The fact that the NRSF binary complex was
remained at the highest amount of Sp3 tested may indicate
that either an additional protein(s) is needed for the efﬁcient
binding in vivo or the two short isoforms of Sp3 produced
during in vitro translation (data not shown) decreased the
actual concentration of the full-length Sp3.
As an additional test of speciﬁc binding of NRSF and Sp3
to NRSE/GC box of MOR gene, we performed EMSA with
NS20Y nuclear extracts. As shown in Figure 6, three major
DNA bound complexes were observed (lane 2). The upper
Figure 3. Mithramycin A enhances the MOR promoter activity. (A) Schematic representation of the promoter constructs pGLNRSP4.7 (wild type) and
pGLNRSPm (mutated the Sp-binding site). (B) NS20Y cells were transfected with the pGL4.7NRSP and pGL4.7NRSPm luciferase reporter gene constructs and
treated with DMSO (as a vechicle) and mithramycin A (100 and 400 nM) for 24 h. The relative luciferase activity of each construct was expressed as the n-fold
increase over the value for the DMSO-treated NS20Y cells. Data were normalized by protein concentration and expressed as the n-fold activation of the
luciferase activity of DMSO-treated activity, which is arbitrarily defined as 1.0. Error bars indicate the range of SE. In addition, the n-fold increase in promoter
activity by mithramycin A compared with the corresponding DMSO-treated control is shown on the top of the error bars.
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or Sp3 antibody (lanes 5 and 6, respectively), whereas
incubation with PI had no effect on the complex (lane 4).
The two lower complexes were not affected (lanes 5 and 6)
by both antibodies, suggesting that these are not related to
NRSF or Sp3. Competitive binding experiments were also
conducted in this EMSA using a 100-fold molar excess of a
self NRSP cold competitor, NRmSP and NRSPm competitor
(lanes 7 and 8, respectively). The self NRSP competitor
competed for protein–DNA interaction efﬁciently (lane 3)
and also mutated competitor NRmSP and NRSPm signiﬁ-
cantly competed for upper complex indicating the speciﬁc
binding of NRSF and Sp3 (lanes 7 and 8). The signal left
after the treatment of the mutated competitor represents the
complex with either NRSF (lane 7) or Sp3 (lane 8). In
PC12 cells (NRSF negative but Sp3 positive), the NRSF-
associated complex (the upper complex in lane 7) was not
detected (data not shown). The subtle shift in mobility (lane
7) or no apparent mobility shift (land 8) may be due to the
presence of various nuclear proteins that were recruited by
both NRSF and Sp3 and/or due to the binding of other nuclear
proteins which have afﬁnity for the probe DNA sequences
that could now be available after the displacement of NRSF
or Sp3 by the mutated competitors.
Interestingly, two lower complexes were dramatically
decreased only when NRSPm competitor was used, suggest-
ing that the bound proteins have speciﬁcity to NRSE region.
Studies investigating the identity of this complex are under-
way.
Taken altogether, the co-immunoprecipitation and EMSA
studies demonstrate that NRSF and Sp3 factor interact with
each other and physically bind to the repressive element of
the MOR promoter, NRSE/GC box.
ChIP and re-ChIP assay revealed that Sp3 and NRSF
were presented together on 188 bp MOR DNA segment
for synergic downregulation of MOR expression
To validate the functional Sp3 binding to MOR promoter
in vivo, we carried out the in vivo ChIP assay using several
antibodies. After cross-linking the proteins and DNAs with
formaldehyde, cell lysates from NS20Y cells were subjected
to immunoprecipitation with NRSF, HDAC1, HDAC2, Sp1,
Sp3 and IRF-4 (as a negative control). The precipitated
DNA fragments were PCR-ampliﬁed with speciﬁc primers
design to generate a 188 bp fragment covering the NRSE
and Sp3-binding GC box in the MOR gene. As shown in
Figure 7A and B, ChIP PCR products were detected with
HDAC2, NRSF and Sp3 antibody, but were not detected
when PI, no antibody or IRF-4 antibody was tested. In
addition, we performed the Re-ChIP assay to verify the Sp3
and NRSF are speciﬁcally co-localized on MOR DNA
(Figure 7C). First, ChIP was performed using anti-NRSF anti-
body. Then, prior to reversal of protein–DNA cross-linking,
the chromatin fragments were subjected to re-precipitation
using anti-Sp1 or anti-Sp3 antibody. During subsequent
PCR only those MOR DNA sequences that are simultane-
ously bound to both NRSF and Sp3 proteins should be
ampliﬁed. As shown in Figure 7C, Sp3, but not Sp1 and
NRSF are speciﬁcally co-localized on the 188 bp MOR pro-
moter sequence containing NRSE and a GC box. The results
clearly demonstrate that NRSF and Sp3 factor bind to the
short MOR promoter segment with close proximity in vivo.
DISCUSSION
Combinatorial interactions between cis-elements and trans--
acting factors are required for the regulation of gene expres-
sion. One of the best-characterized transcription factors for
controlling neuronal gene expression is the repressor element
1 (RE-1)–silencing transcription factor/neuron-restrictive
silencer factor (REST/NRSF) repressor protein that is involved
in suppressing several neuronal gene expressions in non-
neuronal cells (11,12,26–28). We have previously demon-
strated that the NRSE of MOR functions as a critical regulator
to repress MOR gene expression in speciﬁc neuronal cells
depending on NRSF expression level (11). In this study, we
explored the role of the putative Sp transcription factor binding
Figure 4. NRSF interacts with Sp3 factor but not with Sp1 or Sp3 isoforms.
(A) Protein was harvested and immunoprecipitated with NRSF and Sp1 or
Sp3 antibodies. Immune complexes were subjected to western blot analysis
with Sp1 or Sp3 and NRSF antibodies after washing with RIPA buffer (high
stringency, HS) or PBS + 0.5% NP-40 (low stringency, LS). (B and C)
NS20Y cells were transiently transfected with myc-tagged NRSF expression
vector. Protein extract from NS20Y cell was precipitated with anti-c-myc,
anti-Sp1 or anti-Sp3 antibodies, and the immune complexes were subjected to
western blot with anti-Sp3, anti-Sp1 or anti-c-Myc antibodies.
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NRSE and demonstrated that Sp3 transcription factor
represses the expression of MOR gene by binding to this
element and by interacting with NRSF.
From the sequence data analysis, we initially found the
conserved Sp family binding site adjacent to NRSE in
mouse, rat and human MOR gene that could regulate MOR
gene expression. When treated with mithramycin A, a G/C
box speciﬁc binding inhibitor, the mRNA level of MOR
gene was increased in NRSF containing NS20Y cells but
not in NRSF negative PC12 cells (Figure 1). The result
suggested that this GC box element may mainly act as a
repressor in MOR gene regulation and explained why the
MOR transcription level is very low in NS20Y cell line.
To explore the repression mechanism by this GC box in
MOR gene regulation, several MOR-luciferase constructs
with mutations in either NRSE or the G/C box or both
were made and tested for their promoter activities. Mutations
in both NRSE and Sp-binding site showed 14-fold increase in
the activity whereas either NRSE or G/C box mutation had
4- to 5-fold increased activity compared with that of wild-
type sequences in NS20Y cells (Figure 2). Therefore, the
negative effect of the putative Sp-binding element for the
MOR gene expression could be considered as additive to or
preferably synergic with NRSE. A recent study reported
that the transcription levels of the several NRSF target
genes containing GC-rich regions were decreased with
mithramycin A in a dose-dependent manner in both bTC3
and PC12 cells indicating that Sp1 acts as an activator for
the expression of NRSF target genes (29). Two positive Sp
family binding elements in MOR promoter were previously
identiﬁed which is located at  300 bp upstream from the
GC box identiﬁed in the current study (25). In those upstream
elements, Sp1 acts as a major activator by binding to both
elements whereas Sp3 has minor activator effect.
The identity of the transcriptional repressor that binds to
the newly identiﬁed GC box was ﬁrst hinted by co-
immunoprecipitation of the Sp3 factor with NRSF in both
HeLa and NS20Y nuclear extracts (Figure 4). Then, the spe-
ciﬁc and functional binding of Sp3 factor to the GC box was
conﬁrmed by gel-shift assays using either in vitro translated
NRSF and Sp3 factor (Figure 5) or nuclear extract
(Figure 6), and in vivo ChIP assay (Figure 7). The results
clearly demonstrated that Sp3 factor binds the G/C motif
and interacts with NRSF in MOR promoter region, suggest-
ing that transcription factor Sp3 is required for silencing
MOR expression together with NRSF.
Within the Sp family transcription factors, Sp1 and Sp3 are
ubiquitously expressed in mammalian cells. Sp3 is struc-
turally similar to Sp1, with similar afﬁnities for Sp1-binding
site. Although Sp1 and Sp3 share >90% sequence homology
in the DNA-binding domain and they bind to the same cog-
nate DNA element, they have strikingly different functions
(30). Although Sp1 mainly acts as transcriptional activator,
Sp3 can repress activity of the promoter by recruiting
HDAC1 or HDAC2. HDAC1 and HDAC2 have been
shown to potently repress luteinizing hormone receptor
gene transcription. The mSin3A, a component of the Sin3–
HDAC complex, potentiates the inhibition mediated by
HDAC1 (31,32). It has been well established that the Zn
2+-
ﬁnger-containing protein REST/NRSF binds the 21 bp
NRSE DNA element found in many neuronal genes including
Figure 5. Binding of NRSF and Sp3 factor to the negative regulatory region (NRSE/GC box) of MOR promoter. A supershift assay was performed using in vitro
translated myc-tagged NRSF (A) or Sp3 (B) or both (C). EMSAs were performed as indicated in Materials and Methods. (A) Lane 1, probe alone; lane 2,
500-fold molar excess of unlabeled self-competitor probe; lane 3, probe and in vitro translated myc-tagged NRSF; lane 4, c-myc antibody; lane 5, pre-immune
serum (PI); lane 6, non-specific antibody (IRF-4). (B) Lane 1, probe alone and reticulocyte (RBC); lane 2, in vitro translated Sp3; lane 3, PI; lane 4, 500-fold
molar excess of unlabeled self-competitor probe; lane 5, Sp3 antibody; lane 6, non-specific antibody (IRF-4). All lanes contained 4 mlo fin vitro translated NRSF
and Sp3 products from a 50 ml reaction volume (Promega’s in vitro translation kit). (C) Lane 1, probe alone; lane 2, probe and reticulocyte (RBC); lane 3,
probe and in vitro translated myc-tagged NRSF; lane 4, c-myc antibody; lanes 5–9; probe and in vitro translated myc-tagged NRSF with increasing amount of
Sp3 (0.1–2 mg).
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plex that represses gene transcription by deacetylating
histones, methylating both DNA and histone H3, and dephos-
phorylation of RNA polymerase II (15,18,33). In conjunction
with our current data, especially from the co-
immunoprecipitation of Sp3 with NRSF, it can be postulated
that the involvement of Sp3 is needed for the full repression
of MOR gene in addition to NRSF.
An interesting feature of the Sp3 protein family is that, in
addition to a full-length isoform, Sp3 has two short isoforms
which are products of differential translational initiation. It
has been suggested that the short Sp3 isoforms may be res-
ponsible for the transcriptional repression because they
do not have any of the transactivation domains located at the
N-terminus of Sp3 factor (34). However, our current and
previous data strongly suggest that the regulatory action of
Sp3 factors is promoter- and cellular context dependent at
least in the MOR gene expression because (i) only the full-
length Sp3 can interact with NRSF in co-immunoprecipitation
experiment whereas all three isoforms of Sp3 are expressed in
NS20Y cells (Figure 4C), (ii) two short isoforms of Sp3 act
as repressors by binding to the promoter element located at
 219 to  189 of MOR gene (4), (iii) Sp3 acts as a weak posi-
tive element by binding to Sp1 sites at the proximal region
( 450 to  249) of MOR promoter (25).
To our knowledge, this is the ﬁrst report showing that the
sequence-speciﬁc transcription factor (NRSF) has a differen-
tial interaction among Sp3 isoforms to regulate gene expres-
sion. Because two short isoforms are generated by internal
start codon, it can be speculated that the N-terminal region
(112 amino acid residues) of Sp3, which is absent from the
two short isoforms, takes responsibility for the interaction
of the full-length Sp3 with NRSF and for determining the
role of Sp3 factors for MOR gene expression. In addition,
Figure 6. NRSF and Sp3 from NS20Y cell extract bind NRSE/GC box element of MOR promoter. A supershift assay was performed with nuclear extracts from
NS20Y cells. The double-stranded
32P-labeled NRSE/GC box was used as a probe. Lane 1, probe alone; lanes 2–8, probe plus 10 mg of NS20Y cell nuclear
extracts, lane 3, 100-fold molar excess of unlabeled self-competitor; lane 4, PI; lane 5, mouse monoclonal NRSF antibody; lane 6, Sp3 antibody; lane 7, 100-fold
molar excess of NRmSP competitor; and lane 8, 100-fold molar excess of NRSPm competitor.
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factors, such as sumoylation, phosphorylation and acetyla-
tion, may have an important role in determining the fate of
Sp3 factors in the regulation of gene expression (35,36).
Although the exact mechanism of interdependency (or
cooperativity) between NRSF and Sp3 for binding to
NRSE/GC box remains to be elucidated, it is tempting to
speculate that the function of Sp3 could be determined by
the interaction with NRSF. In other words, if NRSF is
abundant in the nucleus, Sp3 interacts with NRSF mainly
acting as a repressor while, when NRSF is depleted in the
nucleus or inactive, Sp3 might bind to the positive elements
and act as a part of Sp1/Sp3 activator complex.
Many researchers eagerly awaited the results of NRSF
loss-of-function experiments in the hope that they would
shed light on the role of NRSF in the regulation of neural
induction. Previous studies clearly indicated that knock-
out of NRSF function is not sufﬁcient to induce either preco-
cious neurogenesis in neural precursors or transformation of
non-neural cells into neurons (26). Our data may suggest
Figure 7. Functional binding of NRSF, Sp3 and HDAC2 at NRSE/GC box at MOR promoter in vivo.( A) Chromatin immunoprecipitation analysis of NRSF, Sp3
and HDAC2 binding at the MOR promoter. ChIPs with PI (sham), anti-IRF4 (sham), anti-NRSF, anti-HDAC1, anti-HDAC2, anti-Sp1 and anti-Sp3 performed on
NS20Y chromatin were amplified with primers flanking the Sp-binding site of the MOR gene. Immunoprecipitated DNA was analyzed by PCR using primers that
amplified a 188 bp region of the MOR promoter, which encompasses a Sp3-binding site. Lane 1, 100 bp DNA marker; lane 2, input; lane 3, without antibody;
lane 4, PI; lane 5, IRF-4 antibody; lane 6, NRSF antibody; lane 7, HDAC1 antibody; lane 8, HDAC2 antibody; lane 9, Sp1 antibody; lane 10, Sp3 antibody. (B)
Quantitative data for ChIPs were analyzed by using ImageQuant 5.2 software. Bars depict the sum of signal intensity in the same size area and SD between
experiments. DNA fragments for input samples were compared with antibody-treated samples, which were assigned a value of 1. (C) Re-ChIP was performed
using anti-NRSF antibody as described in Materials and Methods. Prior to reversal of formaldehyde cross-linking, precipitates were washed, resuspended and
subjected to re-ChIP using anti-Sp1 and anti-Sp3 antibody as described. PCR was then performed as described ChIP assay. Lanes 1, 3 and 7: 100 bp DNA
marker; lane 2: input; lane 4: PI; lane 5: IRF-4 antibody; lane 6: Sp1 antibody; lane 8: PI; lane 9: IRF-4 antibody; lane 10: Sp3 antibody.
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that its function is orchestrated by a symphony of transcrip-
tion factors for the control of target genes. A recent report
identiﬁed that huntingtin protein is mutated in Huntington’s
disease (37). Wild-type huntingtin acts as a positive transcrip-
tional regulator for many NRSE-containing genes involved in
the maintenance of the neuronal phenotype (38). Consis-
tently, loss of expression of NRSE-controlled neuronal
genes is shown in cells, mice and human brain with Hunting-
ton’s disease. In Huntington’s disease, it has been proposed
that mutant huntingtin led to accumulate the NRSF in
nucleus, resulting in the strong repression of the BDNF
which is controlled by NRSE (39). It is probable that the
silencing of NRSF target genes in Huntinton’s disease
could also be the result of additive or synergic repression
through increasing interaction with Sp3 or other transcrip-
tional factors resulting from abnormal presence of NRSF in
neuronal cells.
Emerging evidence indicates that the genetic context is
extremely important in determining the function of NRSE/
NRSF-dependent repression mechanism. In this study, we
demonstrated that Sp3 transcription factor represses the
MOR gene expression by binding to a GC box adjacent to
NRSE and by interacting with NRSF providing evidence
that there is another level of complexity in regulating the
MOR transcription. Detailed elucidation of such synergic
repression mechanism will provide an insight understanding
about the complexity of the transcriptional regulation of
MOR gene as their expression varies in density in different
regions of the central nervous system.
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